Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Killock

Showing results (161-170 of 304) with videos related to

Pageof 31
Sort By:
Nature Reviews. Clinical Oncology|March 30, 2017
Immunotherapy: DLBCL remissions driven by CARsDavid Killock
Nature Reviews. Clinical Oncology|September 6, 2019
DYNAMIC insights into MRD responses early after resection of NSCLCDavid Killock
Nature Reviews. Clinical Oncology|February 22, 2019
CTCs 'piggyback' off neutrophilsDavid Killock
Nature Reviews. Clinical Oncology|August 15, 2022
Promising OS with oncolytic virotherapyDavid Killock
Nature Reviews. Clinical Oncology|November 9, 2022
DREAMseq of therapy for BRAF-mutant melanomaDavid Killock
Nature Reviews. Clinical Oncology|January 4, 2023
Engaging results with glofitamab in DLBCLDavid Killock
Nature Reviews. Clinical Oncology|December 20, 2023
PERSEUS triumphs - efficacy of daratumumab confirmed in transplant-eligible NDMMDavid Killock
Nature Reviews. Clinical Oncology|November 4, 2023
From CHRYSALIS to PAPILLON: the metamorphosis of amivantamab into frontline therapy for NSCLCDavid Killock
Nature Reviews. Clinical Oncology|September 24, 2024
CABINET presents cabozantinib as a new treatment option for NETsDavid Killock
Nature Reviews. Clinical Oncology|June 20, 2019
New daratumumab quadruplets and triplets for newly diagnosed MMDavid Killock
Pageof 31

Showing results (161-170 of 304) with videos related to

Sort By:
Pageof 31
Nature Reviews. Clinical Oncology|March 30, 2017
Immunotherapy: DLBCL remissions driven by CARsDavid Killock
Nature Reviews. Clinical Oncology|September 6, 2019
DYNAMIC insights into MRD responses early after resection of NSCLCDavid Killock
Nature Reviews. Clinical Oncology|February 22, 2019
CTCs 'piggyback' off neutrophilsDavid Killock
Nature Reviews. Clinical Oncology|August 15, 2022
Promising OS with oncolytic virotherapyDavid Killock
Nature Reviews. Clinical Oncology|November 9, 2022
DREAMseq of therapy for BRAF-mutant melanomaDavid Killock
Nature Reviews. Clinical Oncology|January 4, 2023
Engaging results with glofitamab in DLBCLDavid Killock
Nature Reviews. Clinical Oncology|December 20, 2023
PERSEUS triumphs - efficacy of daratumumab confirmed in transplant-eligible NDMMDavid Killock
Nature Reviews. Clinical Oncology|November 4, 2023
From CHRYSALIS to PAPILLON: the metamorphosis of amivantamab into frontline therapy for NSCLCDavid Killock
Nature Reviews. Clinical Oncology|September 24, 2024
CABINET presents cabozantinib as a new treatment option for NETsDavid Killock
Nature Reviews. Clinical Oncology|June 20, 2019
New daratumumab quadruplets and triplets for newly diagnosed MMDavid Killock
Pageof 31